RIPK1 and neurodegenerative disease: These studies identified RIPK1 kinase activity as a key factor contributing to the pathogenesis of inflammatory diseases, prompting the development of RIPK1 kinase inhibitors24–28 that reached clinical trials for the treatment of inflammatory and neurodegenerative diseases as well as pancreatic cancer24,25.